Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2022

26-10-2022 | Mastectomy | Clinical trial

Patterns of breast cancer second recurrences in patients after mastectomy

Authors: Geok Hoon Lim, Veronica Siton Alcantara, Ruey Pyng Ng, Raymond Ng, John Carson Allen, Me Me Win Htein, Swee Ho Lim, Zhiyan Yan, Qing Ting Tan

Published in: Breast Cancer Research and Treatment | Issue 3/2022

Login to get access

Abstract

Introduction

Little is known about second recurrences in breast cancer patients, especially in patients with mastectomy. We aimed to determine the risk factors, prevalence and patterns of second recurrence in mastectomy patients after first recurrence.

Methods

Stage I–III breast cancer patients treated at a tertiary institution from 1st September 2005 to 31st October 2017 and developed first and second recurrences after mastectomy were retrospectively reviewed. We excluded patients with bilateral cancers and patients who were lost to follow-up. The demographics, pathological and recurrence data were collected from a prospectively maintained database and analysed.

Results

Of the 1619 mastectomy patients, 214 (13.2%) patients developed recurrences at a mean 39.9 months from primary cancer diagnosis. 23, 8 and 183 had isolated chest wall recurrences (CWR), regional and systemic metastases, respectively. Excluding 2 CWR patients without surgery, second recurrences occurred in 3/21 (14.3%) and 3/8 (37.5%) in patients with CWR and regional metastasis at 27.7 months (range: 5–42) and 32 months (range: 18–40), respectively. In both groups, systemic metastasis as second recurrence occurred within 2 years after first recurrence, whilst locoregional second recurrences occurred later. No risk factors for second recurrence were identified.

Conclusion

In patients with mastectomy, second recurrences occurred in 20.7% of patients with treated locoregional first recurrence, with no risk factors identified. Systemic metastases manifesting as second recurrence occurred in the first 2 years after first recurrence. Continued clinical surveillance and restaging patients in the first 2 years after first locoregional recurrence may enable early prognostication and treatment with the newer metastatic drugs.
Literature
1.
go back to reference van Maaren MC, de Munck L, Strobbe LJA et al (2019) Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer 144:263–272CrossRefPubMed van Maaren MC, de Munck L, Strobbe LJA et al (2019) Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer 144:263–272CrossRefPubMed
2.
go back to reference Wapnir IL, Gelber S, Anderson SJ et al (2017) Poor prognosis after second locoregional recurrences in the CALOR trial. Ann Surg Oncol 24:398–406CrossRefPubMed Wapnir IL, Gelber S, Anderson SJ et al (2017) Poor prognosis after second locoregional recurrences in the CALOR trial. Ann Surg Oncol 24:398–406CrossRefPubMed
3.
go back to reference Ignatov A, Eggemann H, Burger E et al (2018) Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol 144:1347–1355CrossRefPubMed Ignatov A, Eggemann H, Burger E et al (2018) Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol 144:1347–1355CrossRefPubMed
4.
go back to reference Geurts YM, Witteveen A, Bretveld R et al (2017) Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Res Treat 165:709–720CrossRefPubMedPubMedCentral Geurts YM, Witteveen A, Bretveld R et al (2017) Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Res Treat 165:709–720CrossRefPubMedPubMedCentral
5.
go back to reference Ma J, Jiang R, Fan L et al (2015) Isolated locoregional recurrence patterns of breast cancer after mastectomy and adjuvant systemic therapies in the contemporary era. Oncotarget 6:36860–36869CrossRefPubMedPubMedCentral Ma J, Jiang R, Fan L et al (2015) Isolated locoregional recurrence patterns of breast cancer after mastectomy and adjuvant systemic therapies in the contemporary era. Oncotarget 6:36860–36869CrossRefPubMedPubMedCentral
6.
go back to reference Hwang ES (2014) Breast conservation: is the survival better for mastectomy? J Surg Oncol 110:58–61CrossRefPubMed Hwang ES (2014) Breast conservation: is the survival better for mastectomy? J Surg Oncol 110:58–61CrossRefPubMed
7.
go back to reference Chang JH, Shin KH, Ahn SD et al (2018) Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy. Breast Cancer Res Treat 169:507–512CrossRefPubMed Chang JH, Shin KH, Ahn SD et al (2018) Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy. Breast Cancer Res Treat 169:507–512CrossRefPubMed
8.
go back to reference Montero A, Ciérvide R, García-Aranda M et al (2020) Postmastectomy radiation therapy in early breast cancer: utility or futility? Crit Rev Oncol Hematol 147:102887CrossRefPubMed Montero A, Ciérvide R, García-Aranda M et al (2020) Postmastectomy radiation therapy in early breast cancer: utility or futility? Crit Rev Oncol Hematol 147:102887CrossRefPubMed
9.
go back to reference Gradishar WJ, Anderson BO, Abraham J et al (2020) Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18:452–478CrossRefPubMed Gradishar WJ, Anderson BO, Abraham J et al (2020) Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18:452–478CrossRefPubMed
10.
go back to reference Harbeck N, Bartlett M, Spurden D, Hooper B, Zhan L, Rosta E, Cameron C, Mitra D, Zhou A (2021) CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncol 17:2107–2122CrossRefPubMed Harbeck N, Bartlett M, Spurden D, Hooper B, Zhan L, Rosta E, Cameron C, Mitra D, Zhou A (2021) CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncol 17:2107–2122CrossRefPubMed
11.
go back to reference Keenan TE, Tolaney SM (2020) Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw 18:479–489CrossRefPubMed Keenan TE, Tolaney SM (2020) Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw 18:479–489CrossRefPubMed
13.
go back to reference Exman P, Tolaney SM (2021) HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol 19(1):40–50PubMed Exman P, Tolaney SM (2021) HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol 19(1):40–50PubMed
14.
go back to reference Rosselli Del Turco M, Palli D et al (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. a randomized trial. national research council project on breast cancer follow-up. JAMA J Am Med Assoc. 271:1593–1597CrossRef Rosselli Del Turco M, Palli D et al (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. a randomized trial. national research council project on breast cancer follow-up. JAMA J Am Med Assoc. 271:1593–1597CrossRef
15.
go back to reference Srour MK, Lee M, Walcott-Sapp S et al (2019) Overuse of preoperative staging of patients undergoing neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 26:3289–3294CrossRefPubMed Srour MK, Lee M, Walcott-Sapp S et al (2019) Overuse of preoperative staging of patients undergoing neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 26:3289–3294CrossRefPubMed
16.
go back to reference Tennant S, Evans A, Macmillan D et al (2009) CT staging of loco-regional breast cancer recurrence. a worthwhile practice? Clin Radiol 64:885–90CrossRefPubMed Tennant S, Evans A, Macmillan D et al (2009) CT staging of loco-regional breast cancer recurrence. a worthwhile practice? Clin Radiol 64:885–90CrossRefPubMed
17.
go back to reference Jeong Y, Kim SS, Gong G et al (2015) Prognostic factors for distant metastasis in patients with locoregional recurrence after mastectomy. J Breast Cancer 18:279–284CrossRefPubMedPubMedCentral Jeong Y, Kim SS, Gong G et al (2015) Prognostic factors for distant metastasis in patients with locoregional recurrence after mastectomy. J Breast Cancer 18:279–284CrossRefPubMedPubMedCentral
Metadata
Title
Patterns of breast cancer second recurrences in patients after mastectomy
Authors
Geok Hoon Lim
Veronica Siton Alcantara
Ruey Pyng Ng
Raymond Ng
John Carson Allen
Me Me Win Htein
Swee Ho Lim
Zhiyan Yan
Qing Ting Tan
Publication date
26-10-2022
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2022
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-022-06772-4

Other articles of this Issue 3/2022

Breast Cancer Research and Treatment 3/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine